Compare Gilead Sciences, Inc. (GILD) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Southwest Airlines Co — how do they compare? Gilead Sciences, Inc. trades at $133.11 (market cap $163.51B), while Southwest Airlines Co trades at $49.8 (market cap $24.07B). The key difference: Gilead Sciences, Inc. is far larger — about 6.8× Southwest Airlines Co's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | LUV | |
|---|---|---|
Market Cap | $163.51B | $24.07B |
Sector | Health | Industrials |
52-Week High | $155.80 | $54.80 |
52-Week Low | $108.22 | $29.06 |
Enterprise Value | $178.05B | $27.14B |
Dividend Yield | 2.49% | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Southwest Airlines (LUV) trades at $47.56, down 0.75% on the day, with a mixed technical picture showing bullish signals from moving averages and oscillators but near-term support at $47. Fundamentally, the company reported revenue of $28.06B for 2025 with a net income margin of 2.83%, though earnings missed expectations in Q1 2026. Recent news highlights upcoming Q2 2026 earnings on July 23, 2026, with analysts focused on travel demand and fuel cost pressures.
The investment outlook balances transformation initiatives and resilient travel demand against significant fuel price volatility and execution risks. Analyst consensus is mixed with a $52.47 price target, representing ~10% upside, but risks include lack of fuel hedging and competitive pressures. The stock's valuation at a P/E of 32.83 appears elevated relative to historical airline multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
